Literature DB >> 1732763

Electrophysiologic studies in the Guillain-Barré syndrome: effects of plasma exchange and antibody rebound.

S Rudnicki1, F Vriesendorp, C L Koski, R F Mayer.   

Abstract

Nerve conduction studies (NCS) and antiperipheral nerve myelin antibody (A-PNM Ab) titers were measured serially in 29 patients with Guillain-Barré syndrome (GBS), of whom 21 were treated with plasmapheresis. Data were obtained from 3 to 6 days until 1 to 2 years after onset of symptoms. Within 3 to 6 days, mean NCS were abnormal. They improved some by 1 week and became maximally abnormal by 4 to 8 weeks, during which time A-PNM Ab fell to low levels. In 5 patients plasmapheresed, A-PNM Ab fell and then increased at 4 to 8 weeks, followed by significant deterioration of NCS (P = 0.01) compared with those without antibody rebound at 18 weeks. These results suggest that, in monophasic GBS, there may be two mechanisms of conduction dysfunction such as early paranodal retraction and later demyelination. In some patients plasmapheresed, A-PNM Ab may rebound associated with further conduction dysfunction. These patients may benefit from further plasmapheresis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1732763     DOI: 10.1002/mus.880150111

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  3 in total

1.  Electrophysiological studies in Guillain-Barré syndrome: correlation with antibodies to GM1, GD1B and Campylobacter jejuni.

Authors:  F J Vriesendorp; W J Triggs; R F Mayer; C L Koski
Journal:  J Neurol       Date:  1995-07       Impact factor: 4.849

2.  The acute paralysis in Guillain-Barré syndrome is related to a Na+ channel blocking factor in the cerebrospinal fluid.

Authors:  H Brinkmeier; K H Wollinsky; P J Hülser; M J Seewald; H H Mehrkens; H H Kornhuber; R Rüdel
Journal:  Pflugers Arch       Date:  1992-09       Impact factor: 3.657

Review 3.  Guillain-Barré syndrome: epidemiology, pathophysiology and management.

Authors:  Satoshi Kuwabara
Journal:  Drugs       Date:  2004       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.